Placental Stem Cell Secretome Tested as GvHD Treatment in Phase 3 Trial
A completed Phase 3 trial tests placental MSC secretome injections against placebo in 60 GvHD patients at an Iranian hospital.
Summary
Graft-versus-host disease (GvHD) is a life-threatening complication after bone marrow transplantation where donor immune cells attack the recipient's body. Existing treatments are limited and often fail. This completed Phase 3 trial enrolled 60 GvHD patients at Shahid Qazi Hospital in Tabriz, Iran, randomly assigning them to receive either the secretome of placenta-derived mesenchymal stem cells (PMSCs) or a control solution of distilled water in albumin. The secretome — the collection of proteins and signaling molecules released by stem cells — is thought to carry much of the therapeutic benefit of stem cell therapy without requiring live cell transplantation. The trial was triple-blinded with 30 patients per arm. While results have not been published in the abstract, the study design suggests researchers aimed to evaluate whether this cell-free approach could safely and effectively reduce GvHD severity, potentially offering a simpler, more scalable alternative to direct stem cell infusion.
Detailed Summary
Graft-versus-host disease remains one of the most serious and difficult-to-treat complications following allogeneic hematopoietic stem cell transplantation. When donor immune cells recognize the recipient's tissues as foreign, the resulting immune attack can damage multiple organ systems and prove fatal. Current immunosuppressive therapies carry significant side effects and fail in a substantial proportion of patients, creating urgent demand for novel therapeutic approaches.
This Phase 3 clinical trial, sponsored by Tabriz University of Medical Sciences, investigated whether the secretome of placenta-derived mesenchymal stem cells (PMSCs) could offer a safe and effective treatment for GvHD. The secretome — essentially the bioactive cocktail of cytokines, growth factors, exosomes, and proteins released by stem cells — is increasingly recognized as the primary mediator of mesenchymal stem cell therapeutic effects. Using the secretome rather than live cells simplifies manufacturing, storage, and administration, potentially improving scalability and safety.
Sixty GvHD patients were randomized into two groups of 30. The intervention group received PMSC secretome containing 400 micrograms of protein per milliliter administered by injection, while the control group received distilled water dissolved in 20% albumin. The triple-blinded design adds methodological rigor, minimizing performance and detection bias.
The trial is listed as completed, though full results and outcomes data are not available in the abstract. If the secretome demonstrates meaningful clinical benefit — such as reduced GvHD severity scores, improved organ function, or better survival — it could represent a significant advance in cell-free regenerative medicine applicable beyond GvHD to other inflammatory and autoimmune conditions.
Key caveats include the relatively small sample size of 60 patients, a single-center design limiting generalizability, and the absence of published outcome data. The summary is based on abstract and registry information only, and definitive conclusions await peer-reviewed publication.
Key Findings
- Phase 3 trial tested PMSC secretome injections in 60 GvHD patients using a rigorous triple-blind design.
- Secretome contains 400 mcg/mL protein from placenta-derived mesenchymal stem cells, a cell-free therapeutic approach.
- Cell-free secretome strategy may offer safer, more scalable GvHD treatment than live stem cell infusion.
- Trial is completed, but outcome data are not yet available in the public abstract.
- Positive results could extend cell-free regenerative medicine to broader autoimmune and inflammatory diseases.
Methodology
Randomized, triple-blinded, controlled Phase 3 trial with 60 GvHD patients (n=30 per arm) at a single Iranian hospital. Intervention arm received PMSC secretome (400 mcg/mL protein) by injection; control arm received distilled water in 20% albumin. Patient identifiers were coded to maintain confidentiality throughout data collection.
Study Limitations
The summary is based on the clinical trial registry abstract only, as the full study results and peer-reviewed publication are not yet available. The single-center design at one Iranian hospital limits generalizability to broader patient populations. The small sample size of 60 patients may be underpowered to detect modest but clinically meaningful effects or rare adverse events.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.